Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: Results of the German randomized phase III trial

摘要: 8029 Background: Superiority of irinotecan over etoposide in combination with cis- or carboplatin was demonstrated a Japanese and Scandinavian phase III trial. However, both cisplatin-based North American studies could not detect any difference efficacy. We report the final results German randomized trial comparing etoposide/carboplatin (PE) to irinotecan/carboplatin (IP) small cell lung cancer (SCLC) extensive disease. Methods: Chemotherapy-naive disease SCLC patients were randomly assigned receive AUC 5 mg × min/mL either 50 mg/m2 on days 1, 8 15 (IP, Arm A) 140mg/m2 1–3 (EP). IP treatment repeated every 4 weeks, EP 3 weeks. Response assessment performed after cycles 2, 6 months thereafter. Toxicity assessed once weekly. Primary endpoint detection progression free survival (PFS), secondary endpoints overall (OS), response rat...